Maximus Inc designs, develops, and delivers programs enabling people to access vital government services... Show more
Maximus, Inc. is a provider of government services worldwide, operating through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The company delivers program management, consulting, and technology solutions that help governments administer health and human services programs, including Medicaid, Medicare, and workforce services. Its core business model relies on long-term contracts with federal, state, and local governments, often structured on a performance-based or cost-plus basis. This exposure to public-sector spending makes the company sensitive to government budgets, regulatory changes, and contract renewals, factors that have influenced recent stock behavior amid revenue variability in certain segments.
Over the last 30 days, Maximus, Inc. (MMS) stock price moved lower by approximately 7%, closing near $60.14 after trading around $64.54 thirty days prior. The movement was relatively steady with limited volatility, trending downward in a range-bound fashion influenced by post-earnings digestion.
Over the last quarter, the stock declined approximately 23%, falling from levels near $78 to the recent close of $60.14. This broader decline reflected a more sustained downward trend driven by cumulative revenue softness and shifting investor expectations around growth prospects.
The primary catalyst in the 30-day period was the May 7 release of fiscal 2026 second-quarter results. Revenue came in at $1.31 billion, down from $1.36 billion a year earlier, reflecting the absence of prior-year temporary volumes and divestiture effects. Adjusted diluted earnings per share rose to $2.07 from $2.01, supported by margin expansion, with adjusted EBITDA margin reaching 14.4%. Management raised full-year adjusted EBITDA margin guidance by 20 basis points to approximately 14.2% and adjusted diluted EPS guidance to a range of $8.25 to $8.55. Despite these positive profitability updates, the revenue shortfall weighed on sentiment, contributing to the downward price movement as investors focused on top-line softness in the U.S. Services segment.
The quarterly decline was shaped by sustained revenue pressures across the first half of fiscal 2026, including an 8.2% drop in U.S. Services revenue in the first quarter and similar dynamics in the second quarter. Broader industry trends in government services contracting, combined with the wind-down of certain temporary programs and divestiture-related activity, created a challenging backdrop. Macroeconomic conditions, including government budget timing and collection cycles, added to the pressure. Institutional positioning appeared cautious, with the stock trading lower amid these cumulative factors rather than any single event.
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing artificial intelligence trading bots from a much larger library that covers thousands of tickers. These bots employ varied strategies and timeframes, with performance metrics highlighted for relevance and results. The section helps users identify active, top-ranked options without requiring manual screening of the entire platform. Explore the full selection on the Trending AI Robots page to review current opportunities.
Investors should monitor the next quarterly earnings release for updates on revenue trends and organic growth in the U.S. Services segment. Key factors include the pace of Medicaid community engagement regulations, progress on technology-driven cost initiatives, and days sales outstanding (DSO) trends. Broader macroeconomic conditions affecting government spending and contract awards, along with any updates to full-year guidance, will influence sentiment. Potential risks include further revenue variability from contract timing, while catalysts could emerge from margin expansion or new business wins.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MMS advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .
MMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on June 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMS as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MMS turned negative on June 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MMS entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.673) is normal, around the industry mean (15.595). P/E Ratio (8.114) is within average values for comparable stocks, (70.659). MMS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.465). Dividend Yield (0.023) settles around the average of (0.023) among similar stocks. P/S Ratio (0.570) is also within normal values, averaging (8.649).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of business process services to government health and human services agencies
Industry OfficeEquipmentSupplies